Skip to content

EBIT at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Replimune Group logo
Replimune GroupREPL
-$71.87M-8.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$108.54M-28.6%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.91M-427%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Calculated from OnKure Therapeutics, Inc.’s reported figures.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s EBIT?
OnKure Therapeutics, Inc. (OKUR) reported EBIT of -$15.62M in Q1 2026.
How has OnKure Therapeutics, Inc.'s EBIT changed year-over-year?
OnKure Therapeutics, Inc.'s EBIT increased by 8.1% year-over-year, from -$17M to -$15.62M.
What is the long-term trend for OnKure Therapeutics, Inc.'s EBIT?
Over 3 years (2021 to 2025), OnKure Therapeutics, Inc.'s EBIT has grown at a 16.5% compound annual growth rate (CAGR), from -$39.82M to -$62.95M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.